Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Celldex Therapeutics (NQ: CLDX ) 43.86 +4.55 (+11.57%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 25, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Celldex Therapeutics < Previous 1 2 3 4 5 Next > Analyst Expectations For Celldex Therapeutics's Future July 16, 2024 Via Benzinga Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria July 16, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Celldex Therapeutics to Present at Jefferies Healthcare Conference June 04, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Analyst Expectations For Celldex Therapeutics's Future June 03, 2024 Via Benzinga Unveiling 4 Analyst Insights On Celldex Therapeutics May 07, 2024 Via Benzinga Celldex Therapeutics: Q4 Earnings Insights February 26, 2024 Via Benzinga Forecasting The Future: 5 Analyst Projections For Celldex Therapeutics December 20, 2023 Via Benzinga Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024 June 02, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis May 15, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire CLDX Stock Earnings: Celldex Therapeutics Beats EPS, Misses Revenue for Q1 2024 May 06, 2024 CLDX stock results show that Celldex Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. Via InvestorPlace Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update May 06, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire What 7 Analyst Ratings Have To Say About Celldex Therapeutics November 10, 2023 Via Benzinga Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria April 17, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference March 08, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference March 05, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares March 05, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday March 01, 2024 U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday. Via Benzinga Topics Stocks Exposures US Equities Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock February 29, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Celldex Therapeutics Announces Proposed Public Offering of Common Stock February 28, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session February 26, 2024 Shares of Freshpet, Inc. (NASDAQ: FRPT) gained 15.5% to $106.29 after the company reported better-than-expected fourth-quarter financial results. Via Benzinga Celldex Stock Hits 11-Month High, Up 19%, On A Promising New Hives Treatment February 26, 2024 The company tested its treatment in chronic spontaneous urticaria. Almost 38% of patients had "complete control" after 12 weeks. Via Investor's Business Daily Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update February 26, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria February 24, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference February 06, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024 February 05, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Top Picks 2024: Celldex Therapeutics, Inc. January 28, 2024 Celldex Therapeutics is one of our top picks for the year. With very good data and the financing behind it, now could be the time to take advantage of the pullback in shares to initiate and/or add to... Via Talk Markets Top 4 Health Care Stocks That May Crash This Month December 20, 2023 As of Dec. 20, 2023, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. Via Benzinga Celldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx Conference November 27, 2023 From Celldex Therapeutics, Inc. Via GlobeNewswire Biotech Breakthroughs: 3 Revolutionary Stocks Redefining Healthcare November 17, 2023 Are you looking for biotech breakthrough stocks? Here are three revolutionary stocks redefining healthcare. Via InvestorPlace Why Celldex Therapeutics (CLDX) Stock Is Getting Hammered November 08, 2023 Celldex Therapeutics, Inc. (NASDAQ: CLDX) shares are trading lower after the company announced a proposed public offering of 7.425 million shares at $27 per share. Via Benzinga < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.